ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0925

Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis

Megan M. Hanlon1, Catherine Manning1, Kevin Wei1, Ursula Fearon2 and Ellen M. Gravallese3, 1Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 2Trinity College Dublin, Dublin, Dublin, Ireland, 3Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

Meeting: ACR Convergence 2025

Keywords: innate immunity, macrophages, metabolomics, rheumatoid arthritis, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0916–0933) Innate Immunity Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Synovial tissue macrophages (STMs) represent a mixed population of cells contributing to the pathogenesis of rheumatoid arthritis (RA). We identified an enrichment of Secreted phosphoprotein-1 (SPP1) STMs in RA compared to healthy control (HC) synovial tissue. We show SPP1+ STMs are also enriched in individuals at risk for RA (IAR), suggesting they represent an early disease-specific myeloid subset (1). The aim of this study was to uncover the specific contributions of SPP1+ STMs to RA pathogenesis, which may provide opportunities to reinstate joint homeostasis.

Methods: Peripheral blood was obtained from HC and RA patients. CD14+ monocytes were isolated and differentiated either in the presence of M-CSF (50ng/ml) or Ca2+ (2.5 mM) for 7 days to derive Macs or SPP1-expressing-Macs (S-Macs), respectively. Inflammatory cytokine production by these cells, and their defining metabolic parameters were measured by RT-PCR, ELISA and by the Seahorse-XFE technology. Paraffin embedded synovial tissue biopsies were obtained from HC, from RA patients undergoing key-hole arthroscopy, and from seropositive IAR who have no clinical signs of inflammation. Spatial transcriptomics was performed using a custom Xenium 5K+ panel. Only RA patients who fulfilled the revised ACR criteria were included in this study.

Results: RA SPP1+ STMs correlate significantly with clinical inflammation and display the highest expression of glycolytic genes compared to all other STMs. RA S-Macs have increased expression of SPP1 at both the gene and protein level compared to Macs. S-Macs display increased expression of IL-6, TNF, IL-1b and IL-8 and the glycolytic genes HIF1a and HK2 compared to Macs. Importantly, this is more pronounced in cells derived from RA vs HC indicating priming in the RA periphery. RA S-Macs display decreased baseline oxidative phosphorylation and maximal respiratory capacity compared to Macs derived from HC/RA blood, while concomitantly skewing the ECAR/OCR ratio in favor of glycolysis, indicating that RA S-Macs rely heavily on glycolysis. Finally, we conducted Xenium in situ spatial profiling technology to measure RNA expression levels of 5100 genes in unique paraffin-embedded synovial tissue from HC, IAR and RA. We annotated cell clusters (including macrophages, fibroblasts, T, B cells) and identified their localization to serve as a map of the synovial cellular organization across the evolution of disease.

Conclusion: We demonstrate that SPP1+ STMs correlate with clinical inflammation in RA and are metabolically re-programmed towards glycolysis, leading to sustained induction of pro-inflammatory responses. Xenium spatial analysis allows us to determine the cellular interactions and disease stage-specific factors that shape SPP1+ STMs in RA synovium. These cells may thus represent a potential pathway for therapeutic targeting.(1) Hanlon, Megan M et al. “Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset.” Sci Adv. 2024;10(39):eadj1252. doi:10.1126/sciadv.adj1252


Disclosures: M. Hanlon: Quotient, 2; C. Manning: None; K. Wei: 10X Genomics, 5, anaptysbio, 2, Gilead, 5, Merck/MSD, 5, Mestag, 2, Pfizer, 2; U. Fearon: Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Quotient, 2; E. Gravallese: Beam Therapeutics, 11, CRISPR Therapeutics, 11, Editas Medicine, 11, Elsevier, 9, Ginkgo Bioworks, 11, Intellia Therapeutics, 11, New England Journal of Medicine, 1, UpToDate, 9.

To cite this abstract in AMA style:

Hanlon M, Manning C, Wei K, Fearon U, Gravallese E. Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/pathogenic-role-of-spp1-macrophages-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pathogenic-role-of-spp1-macrophages-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology